Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407206 | 0.89 | MAPT (0.40) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL26694357 | 0.89 | MAPT (0.44) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL5302987 | 0.87 | MAPT (0.43) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL10692551 | 0.87 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL905193 | 0.83 | — | — | |
| SCHEMBL28496420 | 0.83 | — | — | |
| SCHEMBL27556323 | 0.83 | — | — | |
| SCHEMBL8617383 | 0.83 | — | — | |
| SCHEMBL1110727 | 0.83 | — | — | |
| SCHEMBL17688556 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0022710-B1 | PROCESS FOR THE PREPARATION OF 1,4-BENZODIAZEPINES | SANOFI S.A. (FR) | 1984-04-18 | — | — | EP | claimed |
| US-6946554-B2 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-0970029-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS INC. (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5650511-A | MULTISTAGE REACTION OF ALDEHYDE OR KETONE WITH NITRILE GROUP TO FORM ENAMINE, REACTION OF ENAMINE WITH BASE TO FORM PYRROLE, THEN REACTION | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1997021653-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0022710-A1 | Process for the preparation of 1,4-benzodiazepines | SANOFI S.A. (FR) | 1981-01-21 | — | — | EP | disclosed |
| US-3966793-A | ORTHO-AMINOARYL KETIMINES | CLIN MIDY (FR) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | ALKBH3, ALKBH2, ALKBH1 | MAPT 4096/4885CACNA1B 4242/4885APBA1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.